Scarica l'app Stockscreener
1.06
4.59%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.09
Aprire:
$1.1
Volume 24 ore:
199.38K
Relative Volume:
0.96
Capitalizzazione di mercato:
$4.38M
Reddito:
$10.48M
Utile/perdita netta:
$-37.74M
Rapporto P/E:
-0.0655
EPS:
-16.1846
Flusso di cassa netto:
$-29.03M
1 W Prestazione:
+11.68%
1M Prestazione:
-5.45%
6M Prestazione:
-60.15%
1 anno Prestazione:
-96.18%
Intervallo 1D:
$1.03
$1.10
Intervallo di 1 settimana:
$0.9239
$1.14
Portata 52W:
$0.9174
$27.00
Jaguar Health Inc Stock (JAGX) Company Profile
Nome
Jaguar Health Inc
Settore
Industria
Telefono
415-371-8300
Indirizzo
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Confronta JAGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.05 | 4.55M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.34 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
809.47 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.35 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.89 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.01 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Iniziato | Rodman & Renshaw | Buy |
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Why Jaguar Health Inc. stock could see breakout soonJuly 2025 Big Picture & Safe Capital Investment Plans - ulpravda.ru
Can Jaguar Health Inc. stock deliver sustainable ROEGDP Growth & Growth Focused Stock Pick Reports - ulpravda.ru
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - The News Journal
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - The Newark Advocate
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders - The Asheville Citizen Times
Jaguar Health reports PS reduction in pediatric intestinal failure study By Investing.com - Investing.com Australia
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - ACCESS Newswire
Experimental drug lets some children rely less on IV nutrition support - Stock Titan
Knight Therapeutics and Jaguar Health Announce Strategic Partnership - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Ventura County Star
Jaguar Health (JAGX) Secures $240,000 FDA Grant for Canine Diarr - GuruFocus
FDA backs study of new treatment for chemo-related diarrhea in dogs - Stock Titan
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts - Norwich Bulletin
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID) - Montgomery Advertiser
Aug Big Picture: Why hedge funds are buying Jaguar Health Inc stock2025 Top Gainers & Community Supported Trade Ideas - moha.gov.vn
Jaguar Health (JAGX) Reports Promising Trials for Crofelemer in UAE - GuruFocus
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - Burlington Free Press
What analysts say about Jaguar Health Inc stockPrice Action Analysis & Free Stock Index Interpretations - earlytimes.in
Why Jaguar Health Inc. stock remains on watchlists2025 Short Interest & Entry and Exit Point Strategies - Улправда
Sell Signal: Why Jaguar Health Inc 1JA0 stock benefits from AI revolution2025 Geopolitical Influence & Weekly Watchlist for Hot Stocks - moha.gov.vn
Aug PreEarnings: How Jaguar Health Inc. stock reacts to oil prices2025 Investor Takeaways & Target Return Focused Stock Picks - Улправда
Can Jaguar Health Inc. stock deliver surprise earnings beatJuly 2025 News Drivers & Momentum Based Trading Ideas - Улправда
Jaguar Health Earnings Notes - Trefis
How Jaguar Health Inc. stock reacts to oil prices2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Why analysts recommend Jaguar Health Inc. (1JA0) stockJuly 2025 Retail & Real-Time Volume Analysis Alerts - DonanımHaber
Will Jaguar Health Inc. stock split attract more investorsQuarterly Market Summary & High Return Trade Opportunity Guides - DonanımHaber
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Pensacola News Journal
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Hornell Evening Tribune
Jaguar Health director gets 5,870 RSUs and 5,870 options | JAGX SEC FilingForm 4 - Stock Titan
Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada
Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com India
Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus
Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan
About Us - FinancialContent
Jaguar Health executes strategic stock exchange agreements - MSN
Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union
Jaguar Health Inc Azioni (JAGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):